Sellas Teases Biomarker-Driven Efficacy Of AML Drug With Phase IIa Results

The company remained tight-lipped on the biomarker driving high response rates for its CDK9 inhibitor SLS009 from a Phase II trial, as a Phase III interim analysis for its AML cancer vaccine galinpepimut-S draws near.

SELLAS Life Sciences Group, Inc. is in a strong position in acute myeloid leukemia (AML) with positive data from a Phase IIa study of SLS009 and the completion of enrollment in its Phase III trial of the cancer vaccine galinpepimut-S (GPS).

The company announced 26 March topline data from the Phase IIa study of SLS009, a CDK9 inhibitor that Sellas in-licensed...